[Adalimumab therapy in Crohn's disdease].
In spite of using biologic agents for treatment of Crohn's disease (CD), the problem of therapy of CD hasn't been resolved yet. As was shown, approximately 60% patients can't continue treatment with Infliximab because of its primary non-response or secondary loss of response or intolerance. The fully-human monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha), Adalimumab, was significantly effective in randomized placebo-controlled studies for induction remission and for maintaining therapy of CD as well. The drug proved to be effective in patient with previous Infliximab experience, independently of the cause of failure treatment.
Baryshnikov
E N
EN
Lazebnik
L B
LB
Parfenov
A I
AI
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000069285:Infliximab; D016032:Randomized Controlled Trials as Topic; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab